reports
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for ...
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 — Oral presentation Tuesday, June 3, 2025 in Chicago — LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Phase 1/2 interim readout data from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 2025 American Soci...
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (R...
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL AmyloidosisRMAT designation potentially streamlines the path to market approval by allowing frequent interactions with FDA and routes to FDA Accelerated Approval and Priority ReviewEnrollment in NEXICART-2 study accelerating; next update planned for H1 2025 LOS ANGELES,CA, Feb. 10, 202...
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of...
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December 2024NXC-201 is the only one-time CAR-T therapy in development for AL AmyloidosisNext program update Q1 2025 AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow affecting ~33,000 patients in the U.S. LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinic...
Immix Biopharma Announces Positive U.S. Clinical Data From First Four ...
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marrow MRD negative (10-6); all patients remain in response as of the data cutoff of Nov 14, 2024Bone marrow MRD negativity predicts future CR; company believes remaining two patients could be confirmed as...
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Resul...
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients LOS ANGELES, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloido...
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 mont...
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of December 9, 2024Best responder duration of response was 31.5 months with complete response ongoing as of December 9, 2024Conference call to discuss results Tuesday, December 10, 2024 4:30 p.m. ET at LOS ANGELES, C...
Immix Biopharma to Host Conference Call for Investors, Analysts and Me...
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media - Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management’s formal remarks, there will be a question-and-answer session. - Conference Call to be held Tuesday, December 10, 2024 at 4:30 p.m. Eastern Time - Interested parties can attend the conference call via Zoom using the following link: LOS ANGELES, CA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” ...
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th Americ...
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients 75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated...
- Sean Conroy
Immix Biopharma - US CAR-T trial progresses to dose expansion
Immix Biopharma’s US-based NEXICART-2 trial continues to make steady progress through the clinic, with the company reporting that the trial has advanced to the dose expansion level of 450m cells, after completing the 150m cell cohort. The Phase Ib/II trial is assessing Immix’s lead CAR-T asset NXC-201 as a first-in-class outpatient treatment for relapsed/ refractory amyloid light chain amyloidosis (r/r ALA). We highlight that both chosen doses in NEXICART-2 trial had elicited complete responses ...
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level ...
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses in prior clinical studiesLead site Memorial Sloan Kettering Cancer Center (MSKCC); 4 disclosed clinical sites so farNXC-201 is the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials AL Amyloidosis, a disorder of plas...
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recogni...
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis ...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
PBF PBF ENERGY INC. CLASS A
OOMA OOMA
MPAA MOTORCAR PARTS OF AMERICA INC.
LANC LANCASTER COLONY CORPORATION
IMMR IMMERSION CORP.
HNRG HALLADOR ENERGY CO.
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
FFIN FIRST FINANCIAL BANKSHARES INC
CTRN CITI TRENDS INC.
CRK COMSTOCK RESOURCES INC.
BEN FRANKLIN RESOURCES INC.
APEI AMERICAN PUBLIC EDUCATION
ATEC ALPHATEC HOLDINGS INC.
DKL DELEK LOGISTICS PARTNERS
MYRG MYR GROUP INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
GBDC GOLUB CAPITAL BDC INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
APPN APPIAN
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ISDR ISSUER DIRECT CORP.
AXR AMREP
ELAN ELANCO ANIMAL HEALTH INC.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
GRWG GROWGENERATION
ONEW ONEWATER MARINE
BILL BILL.COM HOLDINGS
HPK HIGHPEAK ENERGY INC (A)
ABCL ABCELLERA BIOLOGICS
LESL LESLIES
BFLY BUTTERFLY NETWORK INC (A)
INBX INHIBRX
IMMX INC.
NN IMMIX BIOPHARMA INC
NXGL NEXTNAV INC
BIGZ NEXGEL INC
PFHC BLACKROCK INNOVATION AND GROWTH TST
CALC PROFRAC HLDG CORP
ATMU CALCIMEDICA INC.
ET ATMUS FILTRATION TECHNOLOGIES INC
MIO ENERGY TRANSFER LP
PEO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
SUNS PETROLEUM & RESOURCES CORPORATION
XPER SUNRISE REALTY TRUST
OBDE XPERI INC
LOCO OWL ROCK CAPITAL CORP III
LOVE OIL INC.
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL...
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Data from ex-U.S. clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, CA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing ce...
- Jonathan Moreland
PAYC PAYCOM SOFTWARE INC.
HNRG HALLADOR ENERGY CO.
FLDM FLUIDIGM
BEN FRANKLIN RESOURCES INC.
APEI AMERICAN PUBLIC EDUCATION
ATEC ALPHATEC HOLDINGS INC.
DKL DELEK LOGISTICS PARTNERS
BWFG BANKWELL FINANCIAL GROUP
GBDC GOLUB CAPITAL BDC INC.
APPN APPIAN
QNTO QUAINT OAK BANCORP INC.
ELAN ELANCO ANIMAL HEALTH INC.
U UNITY SOFTWARE INC.
ONEW ONEWATER MARINE
INBX INHIBRX
IMMX INC.
PFHC IMMIX BIOPHARMA INC
CALC PROFRAC HLDG CORP
ET CALCIMEDICA INC.
XPER ENERGY TRANSFER LP
NUTX XPERI INC
NUTEX HEALTH INC
- Sean Conroy
Immix Biopharma - Full steam ahead with US CAR-T trial
Immix Biopharma’s second quarter was headlined by intensified clinical activity for lead CAR-T asset NXC-201 (targeting amyloid light chain amyloidosis, ALA), followed by commencement of patient dosing in the US-based NEXICART-2 trial in July 2024. With an 18- to 24-month timeline for full trial enrollment (planned n=40) and top-line data expected in Q2/Q326, we now anticipate a biological license application (BLA) to be filed in H127 (vs 2026 previously). In our view, the development path has b...
- Sean Conroy
Immix Biopharma - US$8m grant to advance novel CAR-T treatment
Immix Biopharma has received a grant of US$8m from the California Institute for Regenerative Medicine (CIRM) to advance clinical development of its lead CAR-T asset, NXC-201, in relapsed/refractory amyloid light chain amyloidosis (r/r ALA). We believe that this backing from the government agency not only bolsters the company’s capital position (cash runway estimated to extend to Q425), but also provides external endorsement of its efforts towards developing the first outpatient CAR-T treatment w...
California Institute for Regenerative Medicine Awards Funding for CAR-...
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Immix Biopharma cell therapy division Nexc...
- Sean Conroy
Immix Biopharma - US CAR-T trial commences patient dosing
Immix has announced that the first patient has been dosed in its Phase Ib NEXICART-2 trial of lead CAR-T asset NXC-201, which took place at lead study site, the Memorial Sloan Kettering Cancer Center. This US-based study will evaluate the safety and efficacy of NXC-201 in approximately 40 patients with relapsed/refractory amyloid light chain amyloidosis (r/r ALA). Management expects the trial to be fully enrolled within 18 months, implying that top-line results could be available in H126. In the...
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CA...
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at MSKCC in its U.S. ...
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. Stifel 2024 Cell Therapy Forum - Immix Biopharma Date:Tuesday, July 9, 2024Presentation: Immix Biopharma to presentLocation:VirtualInvestor Meetings:The IMMX Team will be available for instituti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.